220 related articles for article (PubMed ID: 18931099)
1. Dipeptidyl peptidase-4 inhibition by vildagliptin and the effect on insulin secretion and action in response to meal ingestion in type 2 diabetes.
Dalla Man C; Bock G; Giesler PD; Serra DB; Ligueros Saylan M; Foley JE; Camilleri M; Toffolo G; Cobelli C; Rizza RA; Vella A
Diabetes Care; 2009 Jan; 32(1):14-8. PubMed ID: 18931099
[TBL] [Abstract][Full Text] [Related]
2. Glucagon dynamics during hypoglycaemia and food-re-challenge following treatment with vildagliptin in insulin-treated patients with type 2 diabetes.
Farngren J; Persson M; Schweizer A; Foley JE; Ahrén B
Diabetes Obes Metab; 2014 Sep; 16(9):812-8. PubMed ID: 24612221
[TBL] [Abstract][Full Text] [Related]
3. Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance.
Rosenstock J; Foley JE; Rendell M; Landin-Olsson M; Holst JJ; Deacon CF; Rochotte E; Baron MA
Diabetes Care; 2008 Jan; 31(1):30-5. PubMed ID: 17947341
[TBL] [Abstract][Full Text] [Related]
4. The dipeptidyl peptidase-4 inhibitor vildagliptin improves beta-cell function and insulin sensitivity in subjects with impaired fasting glucose.
Utzschneider KM; Tong J; Montgomery B; Udayasankar J; Gerchman F; Marcovina SM; Watson CE; Ligueros-Saylan MA; Foley JE; Holst JJ; Deacon CF; Kahn SE
Diabetes Care; 2008 Jan; 31(1):108-13. PubMed ID: 17909087
[TBL] [Abstract][Full Text] [Related]
5. Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes.
Ahrén B; Schweizer A; Dejager S; Dunning BE; Nilsson PM; Persson M; Foley JE
J Clin Endocrinol Metab; 2009 Apr; 94(4):1236-43. PubMed ID: 19174497
[TBL] [Abstract][Full Text] [Related]
6. A Protein Preload Enhances the Glucose-Lowering Efficacy of Vildagliptin in Type 2 Diabetes.
Wu T; Little TJ; Bound MJ; Borg M; Zhang X; Deacon CF; Horowitz M; Jones KL; Rayner CK
Diabetes Care; 2016 Apr; 39(4):511-7. PubMed ID: 26786576
[TBL] [Abstract][Full Text] [Related]
7. Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetes.
Azuma K; Rádiková Z; Mancino J; Toledo FG; Thomas E; Kangani C; Dalla Man C; Cobelli C; Holst JJ; Deacon CF; He Y; Ligueros-Saylan M; Serra D; Foley JE; Kelley DE
J Clin Endocrinol Metab; 2008 Feb; 93(2):459-64. PubMed ID: 18042650
[TBL] [Abstract][Full Text] [Related]
8. The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients.
Balas B; Baig MR; Watson C; Dunning BE; Ligueros-Saylan M; Wang Y; He YL; Darland C; Holst JJ; Deacon CF; Cusi K; Mari A; Foley JE; DeFronzo RA
J Clin Endocrinol Metab; 2007 Apr; 92(4):1249-55. PubMed ID: 17244786
[TBL] [Abstract][Full Text] [Related]
9. Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year.
Ahrén B; Pacini G; Foley JE; Schweizer A
Diabetes Care; 2005 Aug; 28(8):1936-40. PubMed ID: 16043735
[TBL] [Abstract][Full Text] [Related]
10. Improved meal-related insulin processing contributes to the enhancement of B-cell function by the DPP-4 inhibitor vildagliptin in patients with type 2 diabetes.
Ahrén B; Pacini G; Tura A; Foley JE; Schweizer A
Horm Metab Res; 2007 Nov; 39(11):826-9. PubMed ID: 17992639
[TBL] [Abstract][Full Text] [Related]
11. The effect of dipeptidyl peptidase-4 inhibition on gastric volume, satiation and enteroendocrine secretion in type 2 diabetes: a double-blind, placebo-controlled crossover study.
Vella A; Bock G; Giesler PD; Burton DB; Serra DB; Saylan ML; Deacon CF; Foley JE; Rizza RA; Camilleri M
Clin Endocrinol (Oxf); 2008 Nov; 69(5):737-44. PubMed ID: 18331607
[TBL] [Abstract][Full Text] [Related]
12. Robust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naïve patients: analysis of pooled vildagliptin monotherapy database.
Pratley RE; Schweizer A; Rosenstock J; Foley JE; Banerji MA; Pi-Sunyer FX; Mills D; Dejager S
Diabetes Obes Metab; 2008 Sep; 10(10):931-8. PubMed ID: 18093207
[TBL] [Abstract][Full Text] [Related]
13. Effect of vildagliptin on glucose and insulin concentrations during a 24-hour period in type 2 diabetes patients with different ranges of baseline hemoglobin A1c levels.
González-Ortiz M; Sánchez-Peña MJ; González-Ortiz LJ; Robles-Cervantes JA; García-Ortega YE; Gómez-Gaitán EA; Pérez-Rubio KG; Martínez-Abundis E
Diabetes Technol Ther; 2013 Jul; 15(7):564-8. PubMed ID: 23617250
[TBL] [Abstract][Full Text] [Related]
14. Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes.
Matikainen N; Mänttäri S; Schweizer A; Ulvestad A; Mills D; Dunning BE; Foley JE; Taskinen MR
Diabetologia; 2006 Sep; 49(9):2049-57. PubMed ID: 16816950
[TBL] [Abstract][Full Text] [Related]
15. Effects of dipeptidyl peptidase IV inhibition on glycemic, gut hormone, triglyceride, energy expenditure, and energy intake responses to fat in healthy males.
Heruc GA; Horowitz M; Deacon CF; Feinle-Bisset C; Rayner CK; Luscombe-Marsh N; Little TJ
Am J Physiol Endocrinol Metab; 2014 Nov; 307(9):E830-7. PubMed ID: 25231186
[TBL] [Abstract][Full Text] [Related]
16. Dipeptidyl peptidase-4 inhibitor (vildagliptin) improves glycemic control after meal tolerance test by suppressing glucagon release.
Okamoto A; Yokokawa H; Sanada H
Drugs R D; 2014 Dec; 14(4):227-32. PubMed ID: 25204760
[TBL] [Abstract][Full Text] [Related]
17. Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes.
D'Alessio DA; Denney AM; Hermiller LM; Prigeon RL; Martin JM; Tharp WG; Saylan ML; He Y; Dunning BE; Foley JE; Pratley RE
J Clin Endocrinol Metab; 2009 Jan; 94(1):81-8. PubMed ID: 18957505
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of vildagliptin in combination with insulin in patients with type 2 diabetes and severe renal impairment.
Lukashevich V; Schweizer A; Foley JE; Dickinson S; Groop PH; Kothny W
Vasc Health Risk Manag; 2013; 9():21-8. PubMed ID: 23378769
[TBL] [Abstract][Full Text] [Related]
19. Quantification of the Contribution of GLP-1 to Mediating Insulinotropic Effects of DPP-4 Inhibition With Vildagliptin in Healthy Subjects and Patients With Type 2 Diabetes Using Exendin [9-39] as a GLP-1 Receptor Antagonist.
Nauck MA; Kind J; Köthe LD; Holst JJ; Deacon CF; Broschag M; He YL; Kjems L; Foley J
Diabetes; 2016 Aug; 65(8):2440-7. PubMed ID: 27207543
[TBL] [Abstract][Full Text] [Related]
20. Clinical evidence and mechanistic basis for vildagliptin's effect in combination with insulin.
Schweizer A; Foley JE; Kothny W; Ahrén B
Vasc Health Risk Manag; 2013; 9():57-64. PubMed ID: 23431062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
